Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
Innate to receive $5M milestone payment from AstraZeneca
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Subscribe To Our Newsletter & Stay Updated
